Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Operating activities    
Net loss $ (47,857,055) $ (17,693,601)
Adjustments to reconcile net loss used in operating activities:    
Depreciation and amortization 1,304,882 3,266,313
Impairment of intangible assets 0 1,449,121
Stock-based compensation 5,349,428 1,942,196
Acquired in-process research and development 25,549,344 0
Deferred taxes 29,000 28,823
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products 0 107,272
Change in fair value of Investment in Aytu (5,207,789) 0
Change in fair value of warrant liability and unit purchase option liability (14,054) (6,823)
Change in value of Guarantee (1,755,000) 0
Change in fair value of contingent consideration 0 (1,009,168)
Changes in assets and liabilities:    
Accounts receivable, net (171,899) (1,798,216)
Other receivables (4,184,225) 5,260,807
Inventory, net 12,274 601,241
Prepaid expenses and other assets (743,983) (140,503)
Accounts payable (548,039) (619,669)
Income taxes payable 288,329 (1,017,804)
Accrued expenses and other liabilities 1,775,039 (6,573,918)
License obligations 0 (1,250,000)
Lease liability, net 9,794 0
Net cash used in operating activities (26,163,954) (17,453,929)
Investing activities    
Proceeds from sale of Investment in Aytu, net 12,836,736 0
Net cash paid in merger with Aevi (1,250,650) 0
Purchase of property and equipment (62,658) (262,011)
Net cash provided by (used in) investing activities 11,523,428 (262,011)
Financing activities    
Proceeds from underwritten public offering, net 35,427,963 8,975,960
Proceeds from registered direct offering, net 5,136,184 0
Proceeds from sale of shares pursuant to common stock private placement, net 3,887,991 3,737,400
Proceeds from exercise of stock options and warrants 92,342 257,993
Proceeds from shares purchased through employee stock purchase plan 132,910 127,537
Restricted Stock Units withheld for taxes (93,869) (33,959)
Payment of contingent consideration 0 (567,911)
Payment of long-term debt 0 (73,026)
Net cash provided by financing activities 44,583,521 12,423,994
Increase (decrease) in cash, cash equivalents and restricted cash 29,942,995 (5,291,946)
Cash, cash equivalents, and restricted cash at beginning of period 3,728,918 10,746,756
Cash, cash equivalents, and restricted cash at end of period 33,671,913 5,454,810
Supplemental disclosures of cash flow information    
Cash paid for interest 0 787,500
Cash paid for taxes 316,000 1,326,025
Supplemental disclosures of non-cash activities    
Issuance of common stock in Aevi Merger 15,495,578 0
Leased asset obtained in exchange for new operating lease liability 376,448 743,025
Cash and cash equivalents 33,391,427 5,250,651
Restricted cash, current 131,844 102,214
Restricted cash, non-current 148,642 101,945
Total cash, cash equivalents and restricted cash $ 33,671,913 $ 5,454,810